Business Wire

PJSC Magnitogorsk Iron and Steel Works: MMKnotifies on second extention of consent solicitation process

17.6.2022 14:42:00 EEST | Business Wire | Press release

Share

PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the second extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent. Guaranteed Notes due 2024.

On 9 June 2022, PJSC Magnitogorsk Iron & Steel Works (the “Guarantor”) announced extension of consent solicitation in relation to the outstanding U.S.$500,000,000 4.375% Notes due 2024 issued by MMK International Capital DAC (the “Issuer”) (ISIN: XS1843434959 (Regulation S) / US553142AA88 (Rule 144A); Common Code: 111730628 (Regulation S) / 111730628 (Rule 144A Common code)) (the “Notes”) on the terms and subject to the conditions set forth in the Consent Solicitation Memorandum dated 6 June 2022 (the “Consent Solicitation Memorandum”). Capitalized terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.

The Guarantor is pleased to announce that significant progress has been made in obtaining support from investors and thanks those Noteholders, who have already submitted their Consent instructions. In response to requests from a number of accounts requiring additional time in order to pass internal approvals and submit their signatures, the Guarantor announces further extension. The Guarantor thanks all investors who have provided their feedback on the terms of Consent and amendments sought. The Guarantor hereby notifies the Noteholders that it has decided to further extend the Consent Deadline period from 16 June 2022 (4 p.m. (London time)) to 30 June 2022 (4 p.m. (London time)) (the “Updated Consent Deadline”).

Amendments to the Consent Solicitation are limited to the Updated Consent Deadline, as outlined above. All other terms of the Consent Solicitation will remain the same.

The Guarantor strongly encourages those Noteholders that have not yet participated in the Consent Solicitation to liaise at their earliest convenience with its Investor Relations department and/or Rybalkin, Gortsunyan, Dyakin and Partners Advocates Bureau (“RGD”) directly to obtain a copy of the Consent Solicitation Memorandum and to discuss other related matters. Noteholders who have already delivered Consent Instructions in the Consent Solicitation will be deemed to have consented to the Amendments unless they validly revoke their Consents prior to the earlier of the Effective time and the Updated Consent Deadline.

All documentation relating to the Consent Solicitation, together with any updates, will be available upon request to RGD at MMKconsentsolicitation2022@rgd.legal. In your communique, please also confirm the aggregate notional amount of the Notes that you hold and the location of the depository.

Noteholders may contact RGD via email at MMKconsentsolicitation2022@rgd.legal if they require assistance.

Should the Noteholders have any additional questions, please contact with the Guarantor’s Investor Relations department via email at: ir@mmk.ru.

ISIN: US5591892048
Category Code: MSCM
TIDM: MMK
LEI Code: 253400XSJ4C01YMCXG44

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR RELATIONS DEPARTMENT
Veronika Kryachko
+7 (3519) 25-75-01
kryachko.vs@mmk.ru

COMMUNICATIONS DEPARTMENT
Dmitriy Kuchumov
+7 (499) 238-26-13
kuchumov.do@mmk.ru

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release

Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc

Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release

Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release

Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye